Mersana Therapeutics Inc (MRSN) — Cash Flow-to-Debt Ratio
Mersana Therapeutics Inc (MRSN) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of $-3.19 Million could theoretically repay 0% of its total liabilities ($122.22 Million) in one year. See MRSN free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mersana Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Mersana Therapeutics Inc across 10 annual periods. For the full cash flow conversion analysis, see how efficiently does Mersana Therapeutics Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Mersana Therapeutics Inc (2015–2024)
Year-by-year debt coverage analysis for Mersana Therapeutics Inc. Check Mersana Therapeutics Inc (MRSN) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.53x | $-82.34 Million | $154.17 Million | ▲ +40.2% |
| 2023 | -0.89x | $-168.88 Million | $189.16 Million | ▼ -338.2% |
| 2022 | -0.20x | $-49.36 Million | $242.28 Million | ▲ +87.7% |
| 2021 | -1.66x | $-139.99 Million | $84.37 Million | ▼ -0.7% |
| 2020 | -1.65x | $-74.70 Million | $45.31 Million | ▲ +28.9% |
| 2019 | -2.32x | $-67.74 Million | $29.22 Million | ▼ -192.7% |
| 2018 | -0.79x | $-55.22 Million | $69.71 Million | ▼ -12.7% |
| 2017 | -0.70x | $-42.68 Million | $60.72 Million | ▼ -457.6% |
| 2016 | 0.20x | $31.59 Million | $160.71 Million | ▲ +216.5% |
| 2015 | -0.17x | $-9.64 Million | $57.10 Million | — |